Compare Charles River Laboratories Intl. Inc (CRL) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $285.2 (market cap $13.46B), while Invesco S&P 500 Low Volatility ETF trades at $75.9. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals.
| CRL | SPLV | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | — |
52-Week High | $282.00 | $77.97 |
52-Week Low | $145.57 | $70.30 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
SPLV trades at $75.63, down slightly by 0.09% with a bullish technical signal supported by moving averages. The ETF maintains quarterly dividend payments of $0.14 and shows strong institutional interest amid market volatility concerns. Recent news highlights growing investor focus on low-volatility strategies as geopolitical tensions and AI bubble fears drive demand for stability-oriented investments.
The outlook remains positive as low-volatility ETFs gain traction during uncertain market conditions. Key opportunities include defensive positioning and consistent dividend income, while risks center on potential underperformance during strong bull markets and concentration in specific sectors. The ETF's historical resilience during downturns supports its defensive appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
